References
- Wang W, Zhang Y, Peng Y, Jin KZ, Li YL, Liang Y, et al. A Ki-67 index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter study. Neuroendocrinology 2021; 111: 752–63. doi: 10.1159/000510159
- Dogan I, Tastekin D, Karabulut S, Sakar B. Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors. J Dig Dis 2022; 23: 493–9. doi: 10.1111/1751-2980.13123
- Al-Toubah T, Pelle E, Valone T, Haider M, Strosberg JR. Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms. J Natl Compr Canc Netw 2021; 20: 29–36. doi: 10.6004/jnccn.2021.7017
- Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268–75. doi: 10.1002/cncr.25425
- Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang YZ, Woltering EA. The role of capecitabine/temozolomide in metastatic neuroendocrine tumors. Oncologist 2016; 21: 671–5. doi: 10.1634/theoncologist.2015-0470
- Arrivi G, Verrico M, Roberto M, Barchiesi G, Faggiano A, Marchetti P, et al. Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis. Cancer Manag Res 2022; 14: 3507–23. doi: 10.2147/cmar.S372776
- Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016; 23: 759–67. doi: 10.1530/erc-16-0147
- Zhang G, Xu Z, Zheng J, Wang M, Ren J, Wei X, et al. Prognostic value of multi b-value DWI in patients with locally advanced rectal cancer. Eur Radiol 2023; 33: 1928–37. doi: 10.1007/s00330-022-09159-7
- Ingenerf M, Kiesl S, Winkelmann M, Auernhammer CJ, Rübenthaler J, Grawe F, et al. Treatment assessment of pNET and NELM after everolimus by quantitative MRI parameters. Biomedicines 2022: 10: 2618. doi: 10.3390/biomedicines10102618
- Yuan W, Yu Q, Wang Z, Huang J, Wang J, Long L. Efficacy of diffusion-weighted imaging in neoadjuvant chemotherapy for osteosarcoma: a systematic review and meta-analysis. Acad Radiol 2022; 29: 326–34. doi: 10.1016/j.acra.2020.11.013
- Luo Y, Pandey A, Ghasabeh MA, Pandey P, Varzaneh FN, et al. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol 2019; 29: 5160–71. doi: 10.1007/s00330-019-06100-3
- Strosberg JR, Cives M, Brelsford M, Black M, Meeker A, Ghayouri M. Identification of response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. J Clin Oncol 2015; 33: 4099. doi: 10.1200/jco.2015.33.15_suppl.4099
- Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4: 296–307. doi: 10.1038/nrc1319
- 14. Baudin E, Bidart JM, Bachelot A, Ducreux M, Elias D, Ruffié P, et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Annalf Oncol 2001; 12 Suppl 2: S79–82. doi: 10.1093/annonc/12.suppl_2.s79
- Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 2011; 96: 3741–9. doi: 10.1210/jc.2011-0666
- Chou WC, Chen JS, Hung YS, Hsu JT, Chen TC, Sun CF, et al. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors. Anticancer Res 2014; 34: 5661–9.
- Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, et al. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology 2012; 95: 344–50. doi: 10.1159/000333853
- Tsai H-J, Hsiao C-F, Chang JS, Chen L-T, Chao Y-J, Yen C-J, et al. The Prognostic and predictive role of chromogranin A in gastroenteropancreatic neuroendocrine tumors – a single-center experience. Front Oncol 2021; 11: 741096. doi: 10.3389/fonc.2021.741096
- de Mestier L, Dromain C, d’Assignies G, Scoazec J-Y, Lassau N, Lebtahi R, et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer 2014; 21: R105–R120. doi: 10.1530/erc-13-0365
- Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52–60. doi: 10.1055/s-0030-1247132
- Merino-Casabiel X, Aller J, Arbizu J, García-Figueiras R, González C, Grande E, et al. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. Clin Transl Oncol 2018; 20: 1522–8. doi: 10.1007/s12094-018-1881-9
- Yao JC, Phan AT, Fogleman D, Ng CS, Jacobs CB, Dagohoy CD, et al. Randomized run-in study of bevacizumab (B) and everolimus (E) in lowto intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol 2010; 28: 4002. doi: 10.1200/jco.2010.28.15_suppl.4002
- Ingenerf MK, Karim H, Fink N, Ilhan H, Ricke J, Treitl KM, et al. Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study. Acta Radiol 2022; 63: 878–88. doi: 10.1177/02841851211024004
- Min JH, Kang TW, Kim YK, Kim SH, Shin KS, Lee JE, et al. Hepatic neuroendocrine tumour: apparent diffusion coefficient as a potential marker of prognosis associated with tumour grade and overall survival. Eur Radiol 2018; 28: 2561–71. doi: 10.1007/s00330-017-5248-3
- Vandecaveye V, Dresen RC, Pauwels E, Binnebeek SV, Vanslembrouck R, Baete K, et al. Early whole-body diffusion-weighted MRI helps predict long-term outcome following peptide receptor radionuclide therapy for metastatic neuroendocrine tumors. Radiol Imaging Cancer 2022; 4: e210095. doi: 10.1148/rycan.210095